JP2015504098A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504098A5
JP2015504098A5 JP2014553507A JP2014553507A JP2015504098A5 JP 2015504098 A5 JP2015504098 A5 JP 2015504098A5 JP 2014553507 A JP2014553507 A JP 2014553507A JP 2014553507 A JP2014553507 A JP 2014553507A JP 2015504098 A5 JP2015504098 A5 JP 2015504098A5
Authority
JP
Japan
Prior art keywords
drug delivery
delivery material
composite drug
material according
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014553507A
Other languages
English (en)
Japanese (ja)
Other versions
JP6282231B2 (ja
JP2015504098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/022466 external-priority patent/WO2013112434A1/en
Publication of JP2015504098A publication Critical patent/JP2015504098A/ja
Publication of JP2015504098A5 publication Critical patent/JP2015504098A5/ja
Application granted granted Critical
Publication of JP6282231B2 publication Critical patent/JP6282231B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014553507A 2012-01-23 2013-01-22 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子 Expired - Fee Related JP6282231B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261589681P 2012-01-23 2012-01-23
US61/589,681 2012-01-23
PCT/US2013/022466 WO2013112434A1 (en) 2012-01-23 2013-01-22 Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation

Publications (3)

Publication Number Publication Date
JP2015504098A JP2015504098A (ja) 2015-02-05
JP2015504098A5 true JP2015504098A5 (enExample) 2016-03-10
JP6282231B2 JP6282231B2 (ja) 2018-02-21

Family

ID=47630595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014553507A Expired - Fee Related JP6282231B2 (ja) 2012-01-23 2013-01-22 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子

Country Status (17)

Country Link
US (5) US20130189369A1 (enExample)
EP (1) EP2806853B1 (enExample)
JP (1) JP6282231B2 (enExample)
KR (5) KR102183727B1 (enExample)
CN (1) CN104136006B (enExample)
AU (3) AU2013212583A1 (enExample)
BR (1) BR112014017969A8 (enExample)
CA (1) CA2861348C (enExample)
DK (1) DK2806853T3 (enExample)
ES (1) ES2821526T3 (enExample)
HU (1) HUE050904T2 (enExample)
IL (2) IL233620A0 (enExample)
MX (1) MX364864B (enExample)
NZ (1) NZ627368A (enExample)
RU (1) RU2672596C2 (enExample)
WO (1) WO2013112434A1 (enExample)
ZA (1) ZA201405091B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6282231B2 (ja) * 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
US20170112936A1 (en) * 2014-05-23 2017-04-27 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
US20150335704A1 (en) * 2014-05-23 2015-11-26 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
CN104306330A (zh) * 2014-09-24 2015-01-28 万特制药(海南)有限公司 一种盐酸美金刚缓释混悬液及其制备方法
US20170079985A1 (en) 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
CN108367079B (zh) 2015-11-12 2022-11-22 灰色视觉公司 用于治疗的聚集性微粒
EP3478285A4 (en) * 2016-06-30 2020-07-22 Durect Corporation DEPOSIT FORMULATIONS
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
EP3621654A4 (en) 2017-05-10 2021-02-17 Graybug Vision, Inc. PROLONGED-RELEASE MICROPARTICLES AND SUSPENSIONS OF THESE INTENDED FOR MEDICAL THERAPY
EP3651800B1 (en) * 2017-07-11 2024-04-10 Sustained Nano Systems LLC Hypercompressed pharmaceutical formulations
CN107595765A (zh) * 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送系统及其制备方法
GB2586975B (en) * 2019-09-09 2024-03-06 Roemex Ltd Device and method for use with subsea pipelines
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form
WO2022198167A1 (en) * 2021-03-15 2022-09-22 Oakwood Laboratories, Llc Microsphere formulations comprising naltrexone and methods for making and using the same
WO2023281406A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
CN116869914A (zh) * 2023-05-30 2023-10-13 庄秉谚 无针注射系统的投递物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
WO1995027481A1 (en) * 1994-04-08 1995-10-19 Atrix Laboratories, Inc. Liquid delivery compositions
AU739469B2 (en) * 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
CN1314452C (zh) * 2002-04-22 2007-05-09 沈阳药科大学 具有适宜相转变温度的眼用原位凝胶制剂
EP1568359A4 (en) * 2002-12-04 2011-05-18 Santen Pharmaceutical Co Ltd DRUG DELIVERY SYSTEM HAVING SUB-CONJUNCTIVAL DEPOSIT
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
AU2008268222B2 (en) * 2007-06-25 2013-12-12 Otsuka Pharmaceutical Co., Ltd. Microspheres having core/shell structure
EP2482804A1 (en) * 2009-10-01 2012-08-08 Evonik Degussa Corporation Microparticle compositions and methods for treating age-related macular degeneration
CN101816627B (zh) * 2010-04-16 2012-03-07 浙江大学 一种协同治疗型多物质缓释滴眼剂及制备方法
CN102100663B (zh) * 2011-01-14 2013-04-17 华南理工大学 一种pH敏感型原位凝胶纳米缓释眼药水的制备方法
JP6282231B2 (ja) * 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子

Similar Documents

Publication Publication Date Title
JP2015504098A5 (enExample)
RU2014134420A (ru) Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе
Ding et al. Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics
Mottaghitalab et al. Silk fibroin nanoparticle as a novel drug delivery system
Chen et al. Preparation, properties and challenges of the microneedles-based insulin delivery system
Jubeli et al. E-selectin as a target for drug delivery and molecular imaging
Rattanakit et al. Extrusion printed polymer structures: a facile and versatile approach to tailored drug delivery platforms
Lam et al. Advanced progress of microencapsulation technologies: In vivo and in vitro models for studying oral and transdermal drug deliveries
Akash et al. Pluronic F127-based thermosensitive gels for delivery of therapeutic proteins and peptides
HK1213503A1 (zh) 药物递送医疗装置
JP2014111603A5 (enExample)
JP7636334B2 (ja) 治療物質の眼投与のための薬物送達組成物及びその使用法
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
WO2015001087A3 (en) Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
MX383077B (es) Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio.
WO2018206749A1 (en) Ocular compositions
WO2016081616A3 (en) Transdermal patch formulations for delivery of water soluble drugs, peptides, proteins and oligosaccharides
Tamaddon et al. Design and development of intraocular polymeric implant systems for long-term controlled-release of clindamycin phosphate for toxoplasmic retinochoroiditis
WO2013039621A3 (en) Methods and systems for making microtablets for drug delivery
WO2016036823A3 (en) Self-assembling drug delivery vehicles with ionically cross-linked drugs
WO2014075203A8 (es) Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina
US20190247312A1 (en) Pharmaceutical preparation for delivery of peptides and proteins
Kulinsky et al. BioMEMs for drug delivery applications
US10383882B2 (en) Chitosan-based matrices and uses thereof